Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMO 103

Next Previous
Drug Profile

OMO 103

Alternative Names: OMO-103

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peptomyc; Vall d-Hebron Research Institute
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Proto-oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteosarcoma
  • Phase I/II Solid tumours
  • Phase I Adenocarcinoma
  • Preclinical Breast cancer; Colorectal cancer
  • No development reported Lung cancer

Most Recent Events

  • 01 Aug 2025 OHSU Knight Cancer Institute plans a phase I pharmacodynamics trial for Adenocarcinoma (Metastatic disease, Late-stage disease) in China (IV) (NCT07089940)
  • 27 Dec 2024 Phase-II clinical trials in Osteosarcoma (Late-stage disease, In adolescents, In adults, In the elderly, Second-line therapy or greater) in Spain (IV) (NCT06650514)
  • 21 Oct 2024 Vall d'Hebron Institute plans a phase II Osteomyc trial in Osteosarcoma (Late-stage disease, In adolescents, In adults, In the elderly, Second-line therapy or greater) (IV) in November 2024 (NCT06650514)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top